Renal Function Determination in Patients With Liver Cirrhosis
NCT ID: NCT02047240
Last Updated: 2016-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
92 participants
OBSERVATIONAL
2013-04-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that glomerular filtration obtained from cystatin-C-derived formulas are more accurate when compared to creatinine-derived formulas with DTPA-Tc99 (diethylene-triamine-pentaacetate- technetium-99) as gold standard.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Renal Function in Cirrhotic Patients
NCT01895114
Haemostatic Imbalance in Patients With Chronic Liver Disease
NCT03589430
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
NCT01773538
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
NCT02434445
Utility of Renal Biomarkers in Cirrhosis
NCT01217983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stability in creatinine levels in the previous three months (variation \<0.3 mg/dL)
* Signed informed consent
Exclusion Criteria
* Hepatocellular carcinoma
* Cerebrovascular events
* Decompensated heart failure
* Drugs that modify serum creatinine levels
* Renal replacement therapy
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ALDO TORRE DELGADILLO
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aldo Torre, MD MSci
Role: STUDY_DIRECTOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FILT01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.